Abliva

Delivering mitochondrial health

English
- English
- Svenska

Abliva
- This is Abliva
  - Delivering mitochondrial health
  - Orphan Drugs
- Relevant publications
Mitochondrial Disease
Research & Development
- Portfolio
- Clinical trials
  - The FALCON Study
Contact
- Privacy policy

Contact

Visiting address:

Abliva AB
Scheeletorget 1
Lund, Sweden

Postal address

Abliva AB
Medicon Village
SE-223 81 Lund
Sweden

E-mail

info@pharming.com

Tel

+31 (0)71 5247 400

Abliva on social media

About us

Abliva

Abliva develops medicines for the treatment of mitochondrial diseas. This congenital, rare and often very severe disease occurs when the cell's energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.

Startpage
Contact

This is Abliva

Delivering mitochondrial health
Orphan Drugs
Relevant publications

Research & Development

Research & Development
KL1333
NV354
Early programs
The FALCON Study

Contact

Abliva AB, member of Pharming Group
Medicon Village
223 81 Lund, Sweden

Phone
+31 (0)71 5247 400

Generel questions
info@pharming.com

We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy

Settings Accept all

Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy

Necessary
These cookies are not optional. They are needed for the website to function.
Statistics
In order for us to improve the website's functionality and structure, based on how the website is used.
Experience
In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
Marketing
By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.

Save Accept all